-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Connect Biopharma Holdings Limited Forecasted to Post FY2022 Earnings of ($2.11) Per Share (NASDAQ:CNTB)
Connect Biopharma Holdings Limited Forecasted to Post FY2022 Earnings of ($2.11) Per Share (NASDAQ:CNTB)
Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) – Investment analysts at Cantor Fitzgerald lowered their FY2022 earnings per share estimates for shares of Connect Biopharma in a research report issued to clients and investors on Thursday, September 15th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($2.11) per share for the year, down from their prior forecast of ($2.10). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($1.89) per share. Cantor Fitzgerald also issued estimates for Connect Biopharma's FY2023 earnings at ($2.11) EPS.
Get Connect Biopharma alerts:Connect Biopharma Stock Performance
Shares of NASDAQ CNTB opened at $1.44 on Monday. The stock's fifty day simple moving average is $1.22 and its 200 day simple moving average is $1.65. Connect Biopharma has a 52-week low of $0.56 and a 52-week high of $25.25.
Hedge Funds Weigh In On Connect Biopharma
A number of hedge funds have recently modified their holdings of the stock. Vident Investment Advisory LLC acquired a new position in shares of Connect Biopharma in the 1st quarter worth $55,000. Ensign Peak Advisors Inc acquired a new position in shares of Connect Biopharma in the 4th quarter worth $131,000. Invesco Ltd. grew its holdings in shares of Connect Biopharma by 135.9% in the 1st quarter. Invesco Ltd. now owns 60,449 shares of the company's stock worth $183,000 after acquiring an additional 34,820 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Connect Biopharma by 184.7% in the 2nd quarter. Renaissance Technologies LLC now owns 66,900 shares of the company's stock worth $58,000 after acquiring an additional 43,400 shares during the last quarter. Finally, Woodline Partners LP acquired a new stake in shares of Connect Biopharma in the first quarter worth $132,000. 27.19% of the stock is currently owned by institutional investors and hedge funds.Connect Biopharma Company Profile
(Get Rating)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
Recommended Stories
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) – Investment analysts at Cantor Fitzgerald lowered their FY2022 earnings per share estimates for shares of Connect Biopharma in a research report issued to clients and investors on Thursday, September 15th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($2.11) per share for the year, down from their prior forecast of ($2.10). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($1.89) per share. Cantor Fitzgerald also issued estimates for Connect Biopharma's FY2023 earnings at ($2.11) EPS.
康乃德生物控股有限公司(納斯達克代碼：CNTB-GET評級)-康託菲茨傑拉德的投資分析師在9月15日星期四發佈給客户和投資者的一份研究報告中下調了對康乃德生物2022財年每股收益的預期。Cantor Fitzgerald分析師L.Chen現在預計，該公司今年的每股收益將為2.11美元，低於此前預測的2.10美元。康託·菲茨傑拉德目前對該股的評級為“增持”。對新浪康乃德生物目前全年收益的普遍預期為每股1.89美元。康託·菲茨傑拉德還發布了康乃德生物2023財年每股收益預期為2.11美元。
Connect Biopharma Stock Performance
康乃德生物股票表現
Shares of NASDAQ CNTB opened at $1.44 on Monday. The stock's fifty day simple moving average is $1.22 and its 200 day simple moving average is $1.65. Connect Biopharma has a 52-week low of $0.56 and a 52-week high of $25.25.
週一，納斯達克中國工商銀行的股價開盤報1.44美元。該股的50日簡單移動均線為1.22美元，200日簡單移動均線為1.65美元。康乃德生物的52周低點為0.56美元，52周高點為25.25美元。
Hedge Funds Weigh In On Connect Biopharma
對衝基金在康乃德生物上發表看法
Connect Biopharma Company Profile
康乃德生物公司簡介
(Get Rating)
(獲取評級)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
康乃德生物控股有限公司是一家臨牀階段的生物製藥公司，專注於發現和開發用於治療嚴重自身免疫性疾病和炎症的免疫調節劑。該公司的主要候選產品是CBP-201，這是一種抗白細胞介素4受體α抗體，正處於IIb階段臨牀試驗，用於治療炎症性過敏性疾病，如特應性皮炎、哮喘和慢性鼻竇炎伴鼻息肉。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- 在康乃德生物上免費獲取斯托克新聞網研究報告(CNTB)
- 克羅格百貨是你的一站式消費者史泰博股票
- Adobe為投資者完善Facebook工廠的藝術
- 税收抵免是《降低通貨膨脹法案》中的激勵措施
- 股市：紅海中的三座強國
- 第四季度值得考慮的3家銀行
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受康乃德生物日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對康乃德生物及相關公司評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧